The Second Leukotriene Receptor in Human Lung

  • C. Labat
  • J. L. Ortiz
  • I. Gorenne
  • X. Norel
  • P. Gardiner
  • C. Brink
Part of the Developments in Oncology book series (DION, volume 71)

Abstract

While the selective peptido-LT-antagonists ICI 198615 and MK 571 block the LT contractions in bronchial tissues they do not inhibit the vascular responses. These results suggest that more than one leukotriene receptor exists in man. One type is present on human airways (LT-1) and is inhibited by potent antagonists. A second type (LT-2) is present on the pulmonary veins and is resistant to these compounds. Unlike IC1198615 and MK571, LTE4 and BAY u9773 (LT-analog) antagonized LT-induced contractions on the human pulmonary veins. The clinical effect of antagonizing this second peptido-LT receptor type has yet to be assessed.

Keywords

Serotonin Histamine Prostaglandin Hydrochloride Borate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Dahlen S.E., Hedqvist P., Hammarstrom S., Samuelsson B. Nature 288:484–486, 1980.PubMedCrossRefGoogle Scholar
  2. 2.
    Ford-Hutchinson A., Letts G. Hypertension 8 (suppl II): 44–49, 1986.Google Scholar
  3. 3.
    Samuelsson B. Science 220: 568–575, 1983.PubMedCrossRefGoogle Scholar
  4. 4.
    Schellenberg R.R., Foster A. Prostaglandins 27, 475–482, 1984.PubMedCrossRefGoogle Scholar
  5. 5.
    Raffestin B., Cerrina J., Boullet C., Labat C., Benveniste J., Brink C. J. Pharmacol, exp. Ther. 233: 186–194, 1985.Google Scholar
  6. 6.
    Norel X., Labat C., Gardiner P., Brink C. Adv. Prostaglandins Thromboxane and Leukotriene Res. 21: 473–476, 1990.Google Scholar
  7. 7.
    Buckner C.K., Krell R.B., Laravuso, R.B., Coursin D.B., Bernstein P.R., Will J.A. J. Pharmacol, exp. Ther. 237, 558–562, 1986.Google Scholar
  8. 8.
    Jones T.R., Zamboni R., Belly M., Champion E., Charette L., et al., Can. J. Physiol. Pharmacol. 67, 17–28, 1989.PubMedCrossRefGoogle Scholar
  9. 9.
    Gardiner P.J., Abram T.S., Cuthbert N.J. European J. Pharmacol. 182: 291–299, 1990.CrossRefGoogle Scholar
  10. 10.
    Norman P., Abram T.S., Cuthbert N.J., Gardiner P.J. European J. Pharmacol. 182, 301–312, 1990.CrossRefGoogle Scholar
  11. 11.
    Krell R.D., Osborn R., Vickery L., Falcone K., O’Donnell M., Gleason J., Kinzig C., Bryan D. Prostaglandins 22, 387–397, 1981.PubMedCrossRefGoogle Scholar
  12. 12.
    Fleisch J.H., Rinkema L.E., Baker S.R. Life Sci. 31: 577–581, 1982.PubMedCrossRefGoogle Scholar
  13. 13.
    Krell R.D., Tsai B.S., Berdoulay A., Barone M., Giles R.E. Prostaglandins 25:171–178, 1983.PubMedCrossRefGoogle Scholar
  14. 14.
    Tucker S.S., Weichman B.M. Prostaglandins Leukotrienes and Medicine 23: 37–44, 1986.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • C. Labat
    • 1
  • J. L. Ortiz
    • 1
  • I. Gorenne
    • 1
  • X. Norel
    • 1
  • P. Gardiner
    • 2
  • C. Brink
    • 1
  1. 1.CNRS 1159, CCMLLe Plessis-RobinsonFrance
  2. 2.Bayer Ltd.SloughUK

Personalised recommendations